In animals, the chief urinary metabolites of atrazine, simazine & propazine were the corresponding N-dealkyl triazines, 2-chloro-4-amino-6-(ethylamino)-s-triazine and 2-chloro-4-amino-6-(isopropylamino)-s-triazine. A third metabolite, 2-chloro-4,6-diamino-s-triazine, was reported in the urine of rats dosed with the 3 parent cmpd. This cmpd was the major metabolite in rats.
After propazine was administered to lactating goats, 16 metabolites were separated by ion exchange chromatography of urine but not identified. Carbon dioxide was obtained from dealkylation & oxidation of the side chain isopropyl moieties.
...In a goat metabolism study where [14C]propazine was administered orally to a lactating goat at 9.9 ppm (-20x the estimated dietary burden of 0.5 ppm) in the diet for seven consecutive days, total radioactive residues (TRR) were 0.080- 0.238 ppm in milk, 1.123 ppm in liver, 1.041 ppm in kidney, 0.209 ppm in muscle, and 0.160 ppm in fat. The parent propazine was not detected in goat milk or tissues. The chlorometabolite G-28273 (DACT) was the principal residue identified in milk (63.4% TRR, 0.141 ppm), fat (50.4% TRR, 0.080 ppm), muscle (26.1% TRR, 0.054 ppm), and liver (2.7% TRR, 0.031 ppm). The metabolite G-30033 was identified in milk (9.4% TRR, 0.021 ppm) but not in tissues. The remaining radioactivity in goat milk and tissues was characterized to be comprised of up to six unknown metabolites. Although each unknown accounted for <7% TRR in milk, several unknowns were present at significant levels in goat tissues. None of these unknown residues cochromatographed with the 17 reference standards including standards of known chloro- and hydroxy-metabolites of triazine herbicides.
Another goat metabolism study was performed using a radiolabeled hydroxymetabolite of propazine as the test substance. TRR were 0.025-0.029 ppm in milk, 0.006 ppm in muscle, 0.001 ppm in fat (renal and omental), 0.110 ppm in kidney, and 0.036 ppm in liver taken/collected from a lactating goat administered orally with [U-14C]2-hydroxypropazine at 10.9 ppm in the diet for three consecutive days. Residue characterization was not conducted in muscle and fat tissues because of low radioactivity (<0.010 ppm). The test substance, 2-hydroxypropazine, was the major residue identified in all matrices accounting for 63.5% TRR (0.069 ppm) in kidney, 77.2% TRR (0.028 ppm) in liver, and 65.0-69.4% TRR (0.017-0.020 ppm) in milk. The only other metabolite identified was desisopropyl hydroxypropazine, which was detected in minor amounts in all matrices: 2.9% TRR (0.003 ppm) in kidney, 3.6% TRR (0.001 ppm) in liver and 8.2-8.5% TRR (0.002 ppm) in milk.
Propazine is a systemic herbicide that is usually applied to the soil, absorbed through leaves and roots, and acts by inhibiting photosynthesis within the targeted plant. It is used as a selective herbicide to control most annual grasses and broadleaf weeds before the weeds emerge or after removal of weed growth. Propazine is formulated as a flowable concentrate, is registered for use on container-grown ornamentals in greenhouses, and is to be applied through flood or drench nozzles only. ... Propazine has a low order of acute toxicity via the oral (Category IV), dermal (Category IV), and inhalation (Category III) routes of exposure. It is not an eye or skin irritant, or a dermal sensitizer. In a sub-chronic developmental study, incomplete or absent bone formation or ossification was observed in fetal rats following exposure of pregnant rats to propazine. These developmental effects are presumed to occur after a single exposure and are therefore appropriate for consideration in the acute exposure scenario for dietary risk from food. These adverse effects were the basis for identification of a developmental endpoint for acute dietary exposure to propazine in females ages 13 to 49. The corresponding highest dose or level of exposure at which these adverse effects were not observable in female rats ("no observed adverse effects level" or NOAEL) was 10 mg/kg/day. After subchronic and chronic exposure to propazine, a variety of species were shown to exhibit neuroendocrine effects resulting in both reproductive and developmental consequences that are considered relevant to humans. These neuroendocrine effects are biomarkers of a neuroendocrine mechanism of toxicity that is shared by several other structurally-related chlorinated triazines including atrazine, simazine, and three chlorinated degradates - G-28279 (des-isopropyl atrazine or DIA), and G-30033 (des-ethyl atrazine or DEA), and G-28273 (diaminochlorotriazine or DACT) - the latter two which can result from the degradation of propazine. These six compounds disrupt the hypothalamic-pituitary-gonadal (HPG) axis, part of the central nervous system, causing cascading changes to hormone levels and developmental delays. For propazine, a neuroendocrine endpoint was identified for chronic dietary exposure based on adverse effects of estrous cycle alterations and luteinizing hormone (LH) surge suppression observed in a LH surge study on female rats exposed to atrazine. The corresponding NOAEL was 1.8 mg/kg/day. ... Propazine's two chlorinated degradates, DEA and DACT, are considered to have toxicity equal to the parent compound in respect to their common neuroendocrine mechanism of toxicity. Another degradate, hydroxy-propazine, was identified, which is expected to have a different toxicological profile from propazine based on the toxicological data available for an analogous metabolite for atrazine, hydroxy-atrazine. ...
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌性证据
癌症分类:不太可能对人类致癌
Cancer Classification: Not Likely to be Carcinogenic to Humans
Propazine was originally classified in 1989 as a Group C carcinogen, or possible human carcinogen, and was considered to have a non-threshold mechanism for tumor formation. In other words, a threshold, or dose below which the risk of developing cancer is negligible, had not been identified for propazine. Mode of action data were later received and examined by the Agency in regards to the ability of atrazine to induce mammary tumors in rats through the neuroendocrine mechanism of toxicity the compound shares with propazine. As a result of evidence that the events leading to the tumor formation are species/strain specific and not operative in humans, atrazine was reclassified in 2000 as "not likely to be carcinogenic to humans." Propazine was similarly reclassified in 2005 based on weight-of-evidence that it is not genotoxic and operates via a mode of action for the development of mammary and pituitary tumors in female rats similar to atrazine.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌物分类
对人类不具有致癌性(未被国际癌症研究机构IARC列名)。
No indication of carcinogenicity to humans (not listed by IARC).
来源:Toxin and Toxin Target Database (T3DB)
毒理性
暴露途径
该物质可以通过摄入被身体吸收。
The substance can be absorbed into the body by ingestion.
来源:ILO-WHO International Chemical Safety Cards (ICSCs)
Fate in humans and animals: Propazine is readily absorbed and metabolized in the body. At 72 hours after administration of single oral doses of propazine to rats, 66% of the dose was excreted in the urine and 23% was excreted in the feces. This study also indicated that 77% of the dose was absorbed into the bloodstream from the gastrointestinal tract. At 8 days after the dosing, propazine or its metabolites were detected in the rats' lungs, spleen, heart, kidneys, and brain.
In a metabolism study in rats, propazine was administered as a single gavage dose of 1.0 or 100 mg/kg labeled propazine or as 14-daily doses of unlabeled 1.0 mg/kg propazine followed by a single 1.0 mg/kg labeled dose. Corn oil was the vehicle for all treatments. None of the animals died during the study and overall mass balance for all treatment groups ranged from 97.0 to 105.7%. Absorption of propazine from the gastrointestinal tract was rapid and similar for all study groups and no apparent sex-related differences were found. Based on recoveries from urine/ cage wash and tissues, absorption was 73%. Within 48 hours of treatment, 82-95% of the administered dose was recovered from excreta, predominantly the urine. No specific target organs were identified. Labeled propazine was recovered only in the feces of male and female rats in the single high-dose group and female rats in the low dose group. As presented, it cannot be determined if this represents unabsorbed material or material that underwent enterohepatic circulation. Less than 0.1% of the administered dose was detected as CO2 during a pilot study. Thirteen metabolites were recovered; three of which were identified.
The detection of parent hydroxy derivatives in the course of chlorotriazine degradation by animals has been reported. In rats dosed with (14)C-labeled atrazine, simazine & propazine, only small amt, on the order of a few percent, were observed in urine & feces.
When ring-labeled propazine was administered to rats by stomach tube at rates of 41-56 mg/kg, excretion of radioactive material was most rapid during the first 24 hr and decreased to trace amounts by 72 hr. At this time 65.8% and 23% had been recovered from the urine and feces, respectively. At 4 days, the tissue concentrations of related compounds expressed as propazine varied from 19.8 to 39.3 ppm, the lowest values involving the liver and lung. All of the tissue levels fell slowly, the corresponding range at 8 days being 13.0-30.3 ppm. Concentrations tended to be higher in the eviscerated carcass and especially in the skin.
Absorbed principally through plant roots. ... Following root absorption, it is translocated acropetally in the xylem & accumulates in the apical meristems & leaves of plants.
1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
[EN] 3-[(HYDRAZONO)METHYL]-N-(TETRAZOL-5-YL)-BENZAMIDE AND 3-[(HYDRAZONO)METHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE DERIVATIVES AS HERBICIDES<br/>[FR] DÉRIVÉS DE 3-[(HYDRAZONO))MÉTHYL]-N-(TÉTRAZOL-5-YL)-BENZAMIDE ET DE 3-[(HYDRAZONO)MÉTHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE UTILISÉS EN TANT QU'HERBICIDES
申请人:SYNGENTA CROP PROTECTION AG
公开号:WO2021013969A1
公开(公告)日:2021-01-28
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4, R5 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to methods of controlling weeds using said compositions, and to the use of compounds of Formula (I) as a herbicide.
[EN] HERBICIDALLY ACTIVE HETEROARYL-S?BSTIT?TED CYCLIC DIONES OR DERIVATIVES THEREOF<br/>[FR] DIONES CYCLIQUES SUBSTITUÉES PAR HÉTÉROARYLE À ACTIVITÉ HERBICIDE OU DÉRIVÉS DE CELLES-CI
申请人:SYNGENTA LTD
公开号:WO2011012862A1
公开(公告)日:2011-02-03
The invention relates to a compound of formula (I), which is suitable for use as a herbicide wherein G is hydrogen or an agriculturally acceptable metal, sulfonium, ammonium or latentiating group; Q is a unsubstituted or substituted C3-C8 saturated or mono-unsaturated heterocyclyl containing at least one heteroatom selected from O, N and S, or Q is heteroaryl or substituted heteroaryl; m is 1, 2 or 3; and Het is an optionally substituted monocyclic or bicyclic heteroaromatic ring; and wherein the compound is optionally an agronomically acceptable salt thereof.
Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
申请人:Dow AgroSciences LLC
公开号:US20180279612A1
公开(公告)日:2018-10-04
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).